Mauritio
Member
- Joined
- Feb 26, 2018
- Messages
- 5,669
Very interesting study showing that activating the Farnesoid X Receptor results in lower levels of MUFA and PUFA in the liver.
(Farnesoid X receptor - Wikipedia)
Lowers levels of MUFA are brought on by downregulating genes like SCD1.
"Elevated expression levels of SCD1 is found to be correlated with obesity [20] and tumor malignancy.[21]"
(Stearoyl-CoA desaturase-1 - Wikipedia)
Lower levels of PUFA were caused by lower absorption of it from the intestines.
Interestingly, levels of saturated fats were not affected by activating FXR, thereby shifting the ratio of saturated:unsaturated fats in a favorable direction.
I think lower levels of PUFA (and to a lesser degree MUFA) in the liver could bring about all kinds of positive changes: better conversion of T4 to T3, less inflammation/NAFLD/NASH, better detoxification of endotoxin and estrogens,...
Activators of FXR are:
Progesterone, Pregnenolone, Ivermectin, Androsterone, Bile acids, Cafestol...
"FXR activation in mice or humans specifically reduces hepatic levels of mono- and polyunsaturated fatty acids (MUFA and PUFA). Decreases in MUFA are due to FXR-dependent repression of Scd1, Dgat2, and Lpin1 expression, which is independent of SHP and SREBP1c. FXR-dependent decreases in PUFAs are mediated by decreases in lipid absorption."
(Farnesoid X receptor - Wikipedia)
Lowers levels of MUFA are brought on by downregulating genes like SCD1.
"Elevated expression levels of SCD1 is found to be correlated with obesity [20] and tumor malignancy.[21]"
(Stearoyl-CoA desaturase-1 - Wikipedia)
Lower levels of PUFA were caused by lower absorption of it from the intestines.
Interestingly, levels of saturated fats were not affected by activating FXR, thereby shifting the ratio of saturated:unsaturated fats in a favorable direction.
I think lower levels of PUFA (and to a lesser degree MUFA) in the liver could bring about all kinds of positive changes: better conversion of T4 to T3, less inflammation/NAFLD/NASH, better detoxification of endotoxin and estrogens,...
Activators of FXR are:
Progesterone, Pregnenolone, Ivermectin, Androsterone, Bile acids, Cafestol...
"FXR activation in mice or humans specifically reduces hepatic levels of mono- and polyunsaturated fatty acids (MUFA and PUFA). Decreases in MUFA are due to FXR-dependent repression of Scd1, Dgat2, and Lpin1 expression, which is independent of SHP and SREBP1c. FXR-dependent decreases in PUFAs are mediated by decreases in lipid absorption."
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption - PubMed
FXR agonists are used to treat non-alcoholic fatty liver disease (NAFLD), in part because they reduce hepatic lipids. Here, we show that FXR activation with the FXR agonist GSK2324 controls hepatic lipids via reduced absorption and selective decreases in fatty acid synthesis. Using comprehensive...
pubmed.ncbi.nlm.nih.gov
Last edited: